Insmed shares jump on reports Sanofi is weighing a takeover bid
Insmed shares rose 19% after Bloomberg reported Sanofi is working with advisers on a possible acquisition. RBC sees fair value near $195 a share.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Insmed shares rose 19% after Bloomberg reported that Sanofi is consulting advisers while it evaluates a possible acquisition of the drugmaker.
RBC analyst Leonid Timashev, as cited by Seeking Alpha, puts Insmed's fair value at about $195 a share and calls a 20–50% premium plausible. He argues that Sanofi's focus on immunology and the approval of Dupixent for COPD and asthma create a strong rationale for combining assets. He also noted that Sanofi would need to lever up notably to fund a deal of this size.
UBS analyst Ashwani Verma, who rates the stock Buy, points to a 52-week high of $212.75 and calls a potential deal a 'revival trade', similar to earlier AMGN–HZNP and SNY–BPMC transactions.
why it matters
Takeover talk typically supports the shares of the target company, but the deal is not confirmed and would require Sanofi to take on significantly more debt. Investors will watch whether the discussions move to formal negotiations.
market impact
Insmed shares: takeover talk with Sanofi supports the stock
- Insmed shares pressure up — gains on reports that Sanofi may be considering an acquisition
tags
instruments
sources
- Insmed may be worth $170 to $210 a share in takeover, analyst — Seeking Alpha, 19 November 2026 at 19:01 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗